Picture of an older couple dancing on the beach.

TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR)

A paradigm shift in the management of patients with severe aortic stenosis
LEARN ABOUT MEDTRONIC TAVR

Evolut Pro 29mm Product

A MINIMALLY INVASIVE OPTION FOR THE TREATMENT OF SEVERE AORTIC STENOSIS

TAVR is a minimally invasive, catheter-based procedure to replace the function of the aortic valve. Indicated for patients at intermediate or greater risk for open heart surgery, TAVR may be an excellent option for certain patients because the prevalence of aortic stenosis and co-morbidities may increase the risks associated with surgical aortic valve replacement (SAVR).

The Evolut™ TAVR System is the only TAVR platform on the market that demonstrates significantly better outcomes in all-cause mortality or stroke over surgery in high-risk patients at 3 years.1

INDUSTRY-LEADING

HEMODYNAMICS

At one year, 89% of patients had none/trace PVL.2

SEE STUDY RESULTS

REAL-WORLD

RESULTS

Five-year results demonstrated meaningful treatment for patients with severe symptomatic aortic stenosis.3

VIEW RESULTS

EXCELLENT PROCEDURAL

OUTCOMES

Evolut PRO 30-day results:2

  • 1.7% all-cause mortality
  • 1.7% disabling stroke
  • 11.7% permanent pacemaker

SEE OUTCOMES
1

Deeb, et. al, J Am Coll Cardiol. 3-Year Outcomes in High-Risk Patients Who Underwent Surgical or Transcatheter Aortic Valve Replacement, 2016 Jun 7;67(22):2565-74.

2

Williams, et. al, presented at ACC 2018, 1-year outcomes with the Evolut PRO Self-Expanding Repositionable Transcatheter Aortic Valve with Pericardial Wrap

3

Petrossian, et. al, presented at ACC 2018, Clinical Outcomes at 5 Years Following Self-Expanding Transcatheter Aortic Valve Replacement in the CoreValve US Extreme Risk Pivotal Trial.